India's Biocon, Asia's premier biotechnology company, has named Siddharth Mittal as its new chief executive and joint managing director. 3 December 2019
Vancouver, Canada-based regenerative medicine company NervGen Pharma announced the appointment of Paul Brennan as president and chief executive effective immediately. 28 November 2019
Kite Pharma, which was acquired in 2017 by Gilead Sciences in a transaction valued at around $12 billion, announced two new additions to the company’s leadership team. 22 November 2019
US therapeutic gene editing company Sangamo Therapeutics has appointed Sung Lee as executive vice president and chief financial officer, effective October 31, 2019. Mr Lee oversees finance, facilities and information technology functions for Sangamo and reports to the firm’s chief executive. 2 November 2019
USA-based biotech Ovid Therapeutics has made two senior leadership changes to further build the company’s capabilities as it approaches top-line results from the pivotal Phase III NEPTUNE trial for OV101 in Angelman syndrome, expected in mid-2020. 2 November 2019
Genmab, one of the world’s most notable biotech success stories of recent years, has announced that one of those who helped to drive its rapid growth is to retire. 1 November 2019
UK biotech start-up Achilles Therapeutics today announced the appointment of Beverley Carr as chief business officer, with effect from November 4, 2019. 21 October 2019
US biotech Gilead Sciences today announced that Andrew Dickinson has been appointed chief financial officer (CFO), effective November 1. 15 October 2019
Handan He has left her role as global head of computational, biopharmaceutics and translational PK/PD at Novartis’ pharma unit to join Ascletis as chief scientific officer. 8 October 2019
Phathom Pharmaceuticals has announced that Terrie Curran will be appointed chief executive effective upon the closing of the acquisition of Celgene Corp by Bristol-Myers Squibb, 4 October 2019
Tridek-One, a privately-held French biotech specializing in the development of products for the treatment of immune and inflammatory disorders, has named three new members of its executive team. 2 October 2019
Canada’s ImmunoPrecise Antibodies, a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of industry professional Dr Stefan Lang as chief business officer (CBO). 1 October 2019
The UK government-backed Cell and Gene Therapy Catapult (CGT Catapult) has announced that its chief executive, Keith Thompson, is to retire from April 2020. 26 September 2019
UK-headquartered DNA Damage Response (DDR) company Artios Pharma today announces the appointment of Tania Dimitrova as chief business officer and its expanded presence in the USA. 24 September 2019
In a surprise change of leadership at Akcea Therapeutics, Paula Soteropoulos, chief executive, Sarah Boyce, president, and Jeff Goldberg, chief operating officer, have all resigned with immediate effect. 23 September 2019
Privately-held oncology specialist Rgenix says that Robert Wasserman, has joined the Rgenix management team as its new chief medical officer. 19 September 2019
Shares of Alexion Pharmaceuticals dipped 1.3% to $106.44 in after-hours trading on Tuesday, after the US biotech company announced plans for the transition of executive vice president and chief financial officer Paul Clancy later this year. 18 September 2019
French Blood Bank biotech spin-out PDC*line Pharma today announced that Dr Channa Debruyne joined the company in August as medical director, to lead the clinical research team. 9 September 2019
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024